NERV: Minerva Neurosciences Corp Average Forecast Price
Minerva Neurosciences (NERV) minimizes operational risks by distributing neurobiological testing across multiple external laboratories. Business growth is driven by high demand in CNS therapy and anticipation of the FDA verdict on its schizophrenia treatment, with the metric standing at 10.37. The price trend illustrated in this chart complements the picture of market niche protection through roluperidone patents.
Analytical breakdowns for Minerva Neurosciences Corp (NERV)
- stock price and consensus target price:
- market capitalization information:
- shareholders' equity book value data:
- issuer credit burden and liquidity indicators:
Debt to Equity Ratio Minerva Neurosciences|NERV - Long-Term Debt to Capital|Current Liabilities to Capital Minerva|NERV - Company Total Debt|Debts to Book Capitalization Minerva Neurosciences Corp|NERV - Company Long-Term Debt|Company Short-Term Loans and Borrowings Minerva Neurosciences|Immediate Liquidity minervaneurosciences.com
- earnings and valuation multiples information:
NERV - Company Net Income|Future Profit Minerva Neurosciences|NERV - P/E Multiple|Market Cap to Projected Earnings Minerva Neurosciences Inc|NERV - Price/Earnings to Growth Ratio|Enterprise Value to Operating Income Before Depreciation Minerva Neurosciences Corp|NERV - Operating profit EBITDA|Net earnings per one share for the last twelve months Minerva Neurosciences|NERV - Earnings per share for the last twelve months|Year-over-year earnings per one share growth for the last 12 months minervaneurosciences.com|NERV - Net earnings per share growth this year|Net earnings per share growth forecast for next year Minerva Neurosciences
Summary company analytics:NERV minervaneurosciences.com
The recruitment of leading neurobiologists to develop schizophrenia therapies builds significant scientific value for Minerva Neurosciences (NERV). By analyzing the consensus price target for the stock, an investor can identify the weighted average fundamental valuation, where a stabilizing trend signals the market's search for the asset's fair value, helping to distinguish a genuine bottom from the risks of capital freeze within a stagnant trend.
Competitors of Minerva Neurosciences
biogen.com - Broker Consensus Forecast|Analyst Consensus Forecast NBIX (Neurocrine Biosciences, Inc.)|Regencell Bioscience Ltd (RGC) - Average Forecast Price|AXSM - Price Target Chart|Fair Value Consensus ACAD (ACADIA Corp)|XENE (Xenon Pharmaceuticals) - Consensus Target|VKTX (vikingtherapeutics.com) - Price Target Chart|Price Target Chart Supernus|Broker Consensus Forecast CPRX (Catalyst Pharma)|Analyst Consensus Forecast DNLI|HRMY - Average Forecast Price|Biohaven Ltd. - Consensus Target|Analyst Consensus Forecast amylyx.com AMLX|TRVI - Price Target Chart|Fair Value Consensus PRAX (Praxis Precision Medicines Inc)|Anavex Corp (AVXL) - Price Target Chart|Average Forecast Price CeriBell EEG (CBLL)|Price Target Chart Prothena Corporation PLC|Consensus Target Alector Therapeutics (ALEC)|Analyst Consensus Forecast ANNX|Analyst Median Target omeros.com|Price Target Chart Neurogene Corp NGNE|ACIU: Broker Consensus Forecast|Voyager Therapeutics - Analyst Consensus Forecast|Average Forecast Price neumoratx.com|Scilex (SCLX) - Price Target Chart|Tevogen Bio Holdings Inc. - Fair Value Consensus|Consensus Target ACOG|Price Target Chart CGTX|Analyst Consensus Forecast IKT|Analyst Consensus Forecast cassavasciences.com (SAVA)|Assertio - Consensus Target|Fair Value Consensus COYA|VTGN - Price Target Chart|OVID (Ovid Therapeutics Inc.) - Broker Consensus Forecast|ABOS: Analyst Consensus Forecast|Average Forecast Price cervomed.com (CRVO)|Consensus Target ATHE|Analyst Consensus Forecast Clene Nanomedicine|Price Target Chart PepGen Inc. (PEPG)|JUNS (jupiterneurosciences.com) - Fair Value Consensus|Price Target Chart Relmada Therapeutics RLMD|annovisbio.com (ANVS) - Average Forecast Price|GRCE - Price Target Chart|Analyst Median Target Firefly Neuroscience, Inc. AIFF|KLTO: Analyst Consensus Forecast|Consensus Target NeuroSense Therapeutics Ltd.|RVPH (Reviva Pharmaceuticals) - Analyst Consensus Forecast|MetaVia, Inc. (MTVA) - Analyst Median Target|Analyst Consensus Forecast NRXS|HSDT - Average Forecast Price|Price Target Chart Passage Bio PASG|NEUP: Broker Consensus Forecast|Athira Pharma, Inc. - Analyst Consensus Forecast|addextherapeutics.com (ADXN) - Consensus Target|ALZN: Analyst Consensus Forecast|Average Forecast Price Cyclerion Therapeutics, Inc. (CYCN)|Price Target Chart Protagenic Therapeutics Inc.|Pasithea (KTTA) - Analyst Median Target|Price Target Chart Cortigent, Inc. (CRGT)|avenuetx.com - Broker Consensus Forecast|Analyst Consensus Forecast BCLI (BrainStorm Cell Therapeutics)|Cara Therapeutics Inc. (CARA) - Average Forecast Price|CHRO - Price Target Chart|Fair Value Consensus ELYM (Eliem Therapeutics)|ITCI (intracellulartherapies.com) - Consensus Target|LBPH (longboardpharma.com) - Price Target Chart|Price Target Chart Marinus Pharmaceuticals, Inc.|Broker Consensus Forecast NKGN (NKGen Biotech Inc)|Analyst Consensus Forecast NRBO|SAGE - Average Forecast Price|Synaptogenix, Inc. - Consensus Target|Analyst Consensus Forecast trevena.com TRVN|VIGL - Price Target Chart|Fair Value Consensus WENA (Anew Medical Inc.)|Cerevel (CERE) - Price Target Chart
